Daiwa Securities Group Inc. Has $2.20 Million Stake in Stryker Co. (SYK)

Daiwa Securities Group Inc. lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 7.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,363 shares of the medical technology company’s stock after buying an additional 848 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Stryker were worth $2,197,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SYK. Atlantic Trust LLC acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $105,000. Centaurus Financial Inc. acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $110,000. NuWave Investment Management LLC grew its position in shares of Stryker by 3,245.0% during the 3rd quarter. NuWave Investment Management LLC now owns 669 shares of the medical technology company’s stock worth $119,000 after buying an additional 649 shares during the period. Kaizen Advisory LLC grew its position in shares of Stryker by 142.6% during the 2nd quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock worth $127,000 after buying an additional 442 shares during the period. Finally, CX Institutional acquired a new stake in shares of Stryker during the 2nd quarter worth approximately $133,000. Institutional investors own 74.71% of the company’s stock.

Stryker stock opened at $171.25 on Friday. Stryker Co. has a fifty-two week low of $146.80 and a fifty-two week high of $179.84. The company has a market cap of $62.39 billion, a P/E ratio of 26.39, a PEG ratio of 2.29 and a beta of 0.64. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 25th. The medical technology company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.01. Stryker had a net margin of 9.31% and a return on equity of 28.00%. The business had revenue of $3.24 billion for the quarter, compared to analyst estimates of $3.26 billion. Analysts expect that Stryker Co. will post 7.28 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 31st. Investors of record on Friday, September 28th were paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 1.10%. The ex-dividend date of this dividend was Thursday, September 27th. Stryker’s payout ratio is 28.97%.

In other Stryker news, VP M Kathryn Fink sold 415 shares of Stryker stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $166.56, for a total value of $69,122.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Katherine Ann Owen sold 37,866 shares of Stryker stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total transaction of $6,317,563.44. Following the completion of the transaction, the vice president now directly owns 11,367 shares in the company, valued at approximately $1,896,470.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,031 shares of company stock worth $6,520,313. Insiders own 7.40% of the company’s stock.

SYK has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a research report on Tuesday, August 7th. Canaccord Genuity reiterated a “buy” rating and set a $185.00 price target on shares of Stryker in a research report on Wednesday, July 25th. Royal Bank of Canada reiterated a “buy” rating and set a $184.00 price target on shares of Stryker in a research report on Wednesday, July 25th. BTIG Research initiated coverage on shares of Stryker in a research report on Thursday, August 16th. They set a “buy” rating and a $187.00 price target for the company. Finally, Cowen set a $195.00 price target on shares of Stryker and gave the stock a “buy” rating in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Stryker currently has a consensus rating of “Buy” and a consensus price target of $181.81.

ILLEGAL ACTIVITY NOTICE: “Daiwa Securities Group Inc. Has $2.20 Million Stake in Stryker Co. (SYK)” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/11/10/daiwa-securities-group-inc-has-2-20-million-stake-in-stryker-co-syk.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: What are earnings reports?

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply